BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36768830)

  • 1. VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen.
    Nounamo B; Jousheghany F; Siegel ER; Post SR; Kelly T; Ferrone S; Kieber-Emmons T; Monzavi-Karbassi B
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
    Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
    J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells.
    Cooney CA; Jousheghany F; Yao-Borengasser A; Phanavanh B; Gomes T; Kieber-Emmons AM; Siegel ER; Suva LJ; Ferrone S; Kieber-Emmons T; Monzavi-Karbassi B
    Breast Cancer Res; 2011 Jun; 13(3):R58. PubMed ID: 21658254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chondroitin sulfate proteoglycan-4 (CSPG4)-specific monoclonal antibody 225.28 in detection of acute myeloid leukemia blasts.
    Fenton M; Whiteside TL; Ferrone S; Boyiadzis M
    Oncol Res; 2015; 22(2):117-21. PubMed ID: 25706398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.
    Kurokawa T; Imai K
    Proc Jpn Acad Ser B Phys Biol Sci; 2024; 100(5):293-308. PubMed ID: 38735753
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kasten BB; Oliver PG; Kim H; Fan J; Ferrone S; Zinn KR; Buchsbaum DJ
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29561763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
    Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSPG4 in cancer: multiple roles.
    Wang X; Wang Y; Yu L; Sakakura K; Visus C; Schwab JH; Ferrone CR; Favoino E; Koya Y; Campoli MR; McCarthy JB; DeLeo AB; Ferrone S
    Curr Mol Med; 2010 Jun; 10(4):419-29. PubMed ID: 20455858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.
    Hsu SC; Nadesan P; Puviindran V; Stallcup WB; Kirsch DG; Alman BA
    J Biol Chem; 2018 Feb; 293(7):2466-2475. PubMed ID: 29196603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
    Egan CE; Stefanova D; Ahmed A; Raja VJ; Thiesmeyer JW; Chen KJ; Greenberg JA; Zhang T; He B; Finnerty BM; Zarnegar R; Jin MM; Scognamiglio T; Dephoure N; Fahey T; Min IM
    Thyroid; 2021 Oct; 31(10):1481-1493. PubMed ID: 34078123
    [No Abstract]   [Full Text] [Related]  

  • 11. Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.
    Eng MS; Kaur J; Prasmickaite L; Engesæter BØ; Weyergang A; Skarpen E; Berg K; Rosenblum MG; Mælandsmo GM; Høgset A; Ferrone S; Selbo PK
    Photochem Photobiol Sci; 2018 May; 17(5):539-551. PubMed ID: 29565434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.
    Geldres C; Savoldo B; Hoyos V; Caruana I; Zhang M; Yvon E; Del Vecchio M; Creighton CJ; Ittmann M; Ferrone S; Dotti G
    Clin Cancer Res; 2014 Feb; 20(4):962-71. PubMed ID: 24334762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chondroitin Sulfate Proteoglycan 4 Provides New Treatment Approach to Preventing Peritoneal Dissemination in Ovarian Cancer.
    Uno K; Koya Y; Yoshihara M; Iyoshi S; Kitami K; Sugiyama M; Miyamoto E; Mogi K; Fujimoto H; Yamakita Y; Wang X; Nawa A; Kajiyama H
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma.
    Rivera Z; Ferrone S; Wang X; Jube S; Yang H; Pass HI; Kanodia S; Gaudino G; Carbone M
    Clin Cancer Res; 2012 Oct; 18(19):5352-63. PubMed ID: 22893632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display.
    Yu X; Qu L; Bigner DD; Chandramohan V
    Protein Eng Des Sel; 2017 Sep; 30(9):639-647. PubMed ID: 28981720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chondroitin sulfate modification of CSPG4 regulates the maintenance and differentiation of glioma-initiating cells via integrin-associated signaling.
    Niibori-Nambu A; Yamasaki Y; Kobayashi D; Angata K; Kuno A; Panawan O; Silsirivanit A; Narimatsu H; Araki N
    J Biol Chem; 2024 Mar; 300(3):105706. PubMed ID: 38309500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human recombinant Fab fragment from combinatorial libraries of a B-cell lymphoma patient recognizes core protein of chondroitin sulphate proteoglycan 4.
    Egami Y; Narushima Y; Ohshima M; Yoshida A; Yoneta N; Masaki Y; Itoh K
    J Biochem; 2018 Jan; 163(1):61-68. PubMed ID: 29036679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.
    Pucciarelli D; Lengger N; Takacova M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
    Int J Oncol; 2015 Jul; 47(1):81-90. PubMed ID: 25997619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer.
    Hsu NC; Nien PY; Yokoyama KK; Chu PY; Hou MF
    Biochem Biophys Res Commun; 2013 Nov; 441(2):514-8. PubMed ID: 24177010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell surface chondroitin sulphate proteoglycan 4 (CSPG4) binds to the basement membrane heparan sulphate proteoglycan, perlecan, and is involved in cell adhesion.
    Tang F; Lord MS; Stallcup WB; Whitelock JM
    J Biochem; 2018 May; 163(5):399-412. PubMed ID: 29462330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.